simeprevirmaart 11, 2019 | klas | Leave a comment
Simeprevir, sold under the trade names Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. It is specifically used for hepatitis C genotype 1 and 4. Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. Cure rates are in 80s to 90s percent. It may be used in those who also have HIV/AIDS.
Warning You will be tested for hepatitis B before starting simeprevir. In people who have had hepatitis B before or carry the virus, the virus has become active again during or after treatment with drugs like this one.
Simeprevir (Olysio) is a NS3/4A hepatitis C virus (HCV) protease inhibitor.Simeprevir is a macrocyclic compound that non-covalently binds to and inhibits the NS3/4A HCV protease, a protein that is responsible for cleaving and processing the HCV-encoded polyprotein, a critical step in HCV viral life cycle.
Several FDA-approved drug labels may be available for simeprevir. AIDSinfo provides the following drug label solely as an example of the labels available for simeprevir. Inclusion or absence of a drug label on the AIDSinfo site does not imply endorsement or lack thereof by AIDSinfo.Search [email protected] to access more information on simeprevir, including additional drug labels and any generic
Simeprevir comes as a capsule to take by mouth. It is usually taken with food once a day. Take simeprevir at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.
Warnings/Precautions. Concerns related to adverse effects: • Hepatic decompensation/failure: Hepatic decompensation and failure (including fatal cases) have been reported in patients treated with simeprevir in combination with peginterferon alfa and ribavirin or sofosbuvir.